Risk of Deadly Skin Cancer May Be Gauged by Accumulated DNA Damage
Risk for melanoma, the most deadly skin cancer, can be estimated long before detection of any suspicious moles, according to a UCSF scientist.
University of California San Francisco
Give to UCSFRisk for melanoma, the most deadly skin cancer, can be estimated long before detection of any suspicious moles, according to a UCSF scientist.
The UCSF researchers — whose work spans investigations into autism spectrum disorder (ASD), oncology, and mitochondrial disease — were among 85 awardees for the grants that the NIH says “will fund highly innovative and unusually impactful biomedical or behavioral research proposed by extraordinarily creative scientists.”
Expanding routine newborn screening to include a metabolic vulnerability profile could lead to earlier detection of life-threatening complications in babies born preterm, according to a study by UC San Francisco researchers.
Though cancer immunotherapy has become a promising standard-of-care treatment – and in some cases, perhaps a cure – for a wide variety of different cancers, it doesn’t work for everyone, and researchers have increasingly turned their attention to understanding why.
Students, faculty and staff at UCSF will be invited to activate COVID Notify on their smartphones.
Researchers at UCSF are tackling antibiotic resistance using a different approach: redesigning existing antibiotic molecules to evade a bacterium’s resistance mechanisms
Movement timelines from cellphone data can help people who have just received a positive test result recall where they have been and who they came into contact with when they were most infectious.
Infectious diseases expert Monica Gandhi, MD, MPH, explores her hypothesis that one of the benefits of masks may be that they provide exposure to enough coronavirus to build immunity but not enough to cause illness.
Researchers have figured out how to assemble genetic profiles of individual lung cancer cells obtained from patients at different times during the course of their treatment.
Though FTD is not as well known as Alzheimer’s disease, it’s the second most common cause of dementia in people under 65, and there’s currently no treatment.
New UCSF research sheds light on how immune system B cells that infiltrate the central nervous system may drive multiple sclerosis.
UCSF scientists now have evidence from research that women with Alzheimer’s live longer than men with the disease because they have genetic protection from the ravages of the disease.
UCSF Osher Center faculty member Ashley Mason, PhD, has received a $5.1M award to expand TemPredict, a study she directs in collaboration with Rick Hecht, MD, and Benjamin Smarr, PhD.
The program will be one of the most comprehensive of its kind in the nation.
Researchers at UCSF have developed a “digital biomarker” that would use a smartphone’s built-in camera to detect diabetes.
UCSF scientists have devised a novel approach to halting the spread of SARS-CoV-2, the virus that causes the disease.
Researchers found that, when used alone, sequencing comes up short, missing some sick babies, while flagging many healthy ones for unnecessary follow-up testing. But sequencing can still be useful in cases that look suspicious but were not clearly identified by older screening technology.
A newly completed phase 3, multicenter clinical trial has found that an immune-modulating drug can silence inflammatory disease activity in a large majority of patients with relapsing multiple sclerosis (RMS) – the most common form of the illness, in which symptoms wax and wane.
The COVID-19 pandemic has led to a significant increase in video visits between patients and their doctors, but for many older adults, the shift has cut them off from care, rather than connecting them.
Some supposedly inert ingredients in common drugs — such as dyes and preservatives — may potentially be biologically active and could lead to unanticipated side effects, according to a preliminary new study by researchers from the UCSF and the Novartis Institutes for BioMedical Research.
Clinical trial leader Annie Luetkemeyer, MD, tests promising therapies for COVID-19 – and soon a vaccine.
How I learned to use social media to advance the public’s understanding of COVID-19.